Phase III Study of HRS-1780 Tablets for Adults With Chronic Kidney Disease to Slow Kidney Function Decline

What this Trial Is About

Researchers are conducting a Phase III clinical trial to evaluate whether HRS-1780 tablets can better delay the decline in kidney function compared to a placebo in adults with chronic kidney disease CKD who are already receiving standard treatment. The study aims to assess the effectiveness and safety of this investigational drug in slowing disease progression over an extended period. Participants will be randomly assigned to receive either HRS-1780 tablets or placebo tablets. Both treatments are taken orally, and the study is designed as a double-blind, placebo-controlled trial to ensure unbiased results. The main treatment period extends up to 60 months, during which kidney function and related health measures will be closely monitored. Throughout the study, participants will undergo various assessments including measurements of kidney function using estimated glomerular filtration rate eGFR, urine albumin-to-creatinine ratio UACR, and blood tests such as HbA1c and serum potassium levels. Researchers will track the time until the first occurrence of a composite kidney-related endpoint, as well as changes in kidney function slopes and UACR values. Safety and health will be monitored regularly, and the total participation duration may last several years to capture long-term effects.

A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease